Log In
Print
BCIQ
Print
Print this Print this
 

MGD010

  Manage Alerts
Collapse Summary General Information
Company MacroGenics Inc.
DescriptionBispecific antibody against Fc gamma receptor IIb (FCGR2B; CD32B) and CD79b molecule immunoglobulin-associated beta (CD79B; B29)
Molecular Target Fc gamma receptor IIb (FCGR2B) (CD32B) ; CD79b molecule immunoglobulin-associated beta (CD79B) (B29)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard Indication Autoimmune (unspecified)
Indication DetailsTreat autoimmune disorders
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$501.5M

0

$468.5M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today